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A commentary on
IL-17 in Chronic Inflammation: From Discovery to Targeting
by Beringer, A., Noack, M., and Miossec, P. (2016). Trends Mol. Med. 22, 230–241. doi:
10.1016/j.molmed.2016.01.001
A recent article titled “IL-17 in chronic inflammation: From discovery to targeting,” by Beringer
et al. (2016), greatly reviewed the biology of interleukin-17 (IL-17) family members highlighting
the contributions of IL-17 cytokines toward diseases and IL-17-based treatment options. Authors
attractively reported how preclinical and clinical studies have provided a solid scientific justification
for targeting IL-17 and/or IL-17 receptor (IL-17RA) in human diseases such as inflammatory and
autoimmune disorders. Here, I wish to implement the description of the biological properties of
IL-17A on the cardiovascular system, the novel underlying mechanisms on platelets aggregation,
and thrombus formation, and to report the contribution of IL-17A/IL-17RA axis in the association
of autoimmune diseases with cardiovascular risk.
AUTOIMMUNE DISEASES AND CARDIOVASCULAR RISK
Autoimmune disorders comprise different diseases including various rheumatologic, dermatologic,
and gastroenterological illnesses. The distinctive feature is the inability of the immune system to
turn off the processes directed against the body after an inflammatory response or to prevent its
development (Mammen, 2011). The etiology of these complex disorders is unknown. However, the
susceptibility to develop autoimmune diseases is due to genetic factors influencing the biochemical
events associated with antigen presentation or the mechanisms involved in the development of
tolerance (Wu et al., 2016).
There is now compelling evidence that patients affected by autoimmune diseases have a
higher incidence of several cardiovascular diseases (Teixeira et al., 2015). It has been suggested
that it may depend on the presence of a mutual network in which systemic inflammation,
coagulation, fibrinolysis, tissue remodeling, and angiogenesis play closely related roles. The
resulting inflammation and organ damage further amplify autoreactive immune responses, forming
a self-sustaining and propagating vicious circle (Alkaabi et al., 2003).
During vascular inflammation, cells of innate and adaptive immunity invade the vessel
wall. Among them, there are T cells, and some of which produce IL-17A, a pro-inflammatory
cytokine produced mainly by a subset of T helper lymphocytes named TH17 (D’Acquisto et al.,
2010). Therefore, a more complete understanding of the molecular mechanisms involved in the
recruitment and activation of TH17 immune response should provide insights into the pathogenesis
and treatment of these and possibly other inflammatory-based diseases.
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INSIGHT INTO THE INVOLVEMENT OF
IL-17A ON AUTOIMMUNE-RELATED
CARDIOVASCULAR DISEASES
TH17 cells are characterized by the production of IL-17A (also
called IL-17), IL-17F, and IL-22 cytokines that are assumed
to be involved in the attack of extracellular pathogens not
effectively handled by either TH1 or TH2 cells. Starting from
the premise that TH17 cells produce great quantities of IL-
17A, most of the TH17-mediated effects are attributed to this
cytokine (D’Acquisto et al., 2010). IL-17A is a pro-inflammatory
cytokine; it is highly produced in patients with chronic
inflammatory diseases such as rheumatoid arthritis, multiple
sclerosis, intestinal bowel disease, and psoriasis (Beringer
et al., 2016). One common feature of patients suffering
from these sustained systemic inflammatory conditions is
the development of cardiovascular complications including an
increased risk of endothelial cell injury, ischemia/reperfusion
damage, platelet hyperactivity, and thromboembolism (Alkaabi
et al., 2003).
In a study done in 2009, it has been demonstrated that
IL-17A in vivo sustains rather than induces inflammation,
thus amplifying an inflammatory response induced by a pre-
existing damage (Maione et al., 2009). In a scientific parallelism,
soon after, it has been reported that this cytokine per se is
unable to induce a pro-aggregating response on murine and
human platelets, whereas it able to sustain and amplify platelet
hyper-reactivity (Maione et al., 2011). Contextually, it has been
reported, for the first time, the presence of a functional role
of IL-17 receptor on murine and human platelets (Maione
et al., 2011). In contrast with the restricted localization of IL-
17, IL-17RA is ubiquitously expressed in different cells and
tissues. Moreover, although the pro-inflammatory function and
intracellular signaling pathway of IL-17 are strikingly similar
to those of IL-1 and Toll receptors, IL-17RA has no homology
with other known receptor sequences, thus making IL-17,
homologous proteins, and its viral homolog a novel cytokine
family. The ubiquitous expression of the IL-17RA gene and its
peculiar sequence strongly suggest the possibility of other, as yet,
unknown biological functions for this cytokine (Yao et al., 1995).
Consistent with this report, following studies have reported
that the combination of IL-17A and TNF-α induces a pro-
inflammatory, pro-coagulant, and pro-thrombotic phenotype
in human endothelial cells (Hot et al., 2012, 2013). Recent
studies also have highlighted that this cytokine facilitates
platelet function through the ERK2 signaling pathway (the main
intracellular pathway activated in platelets by a number of strong
agonist) in patients with acute coronary syndrome (Zhang et al.,
2012) and that neutrophil extracellular traps and IL-17A are
associated with the organization of thrombi in acute myocardial
infarction (de Boer et al., 2013).
Accordingly, recent evidence has also demonstrated that IL-
17A is a mediator of angiogenesis, an essential component of
chronic inflammation and tissue remodeling associated with
autoimmune disorders, which stimulates vascular endothelial cell
migration and modulates the production of a variety of pro-
angiogenic factors (Numasaki et al., 2003). The latter findings
suggest that inhibition of IL-17A may have therapeutic benefits
when applied to angiogenesis-related disorders.
Lastly, but not least important, recent in vivo evidence has
provided preliminary but significant contributions to understand
the pro-thrombotic effect of this cytokine. These results show,
for the first time, that IL-17A is synergic with a low FeCl3
concentration in inducing carotid thrombus in rats and suggest
that the effect is likely related to a downregulation of CD39
vascular expression and hydrolyzing activity (Maione et al.,
2014).
CONCLUSION
Taken together, all these results support the hypothesis that
IL-17A plays a crucial role in the development of chronic
inflammation and probably in the hemostatic disorders observed
in patients with autoimmune diseases. Nevertheless, what
remains to be seen is whether in vitro evidence, results from
animal models and limited ex vivo human studies can contribute
to better understanding of the IL-17A/IL-17RA axis biology in
the context of platelet functionality/hyperactivity and contribute
to develop new therapeutic strategies regarding the effects of
IL-17A on autoimmune-related cardiovascular diseases. We will
see.
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